Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Cyclerion to Host Corporate Overview Call on May 13, 2019
April 25, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Announces the Appointment of Andreas Busch, Ph.D., as Chief Innovation Officer
April 09, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases
April 02, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
– $175 million committed from investors in private placement offering – – Trading of CYCN begins on Nasdaq today – CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics,...
GBT Announces New Employment Inducement Grants
November 06, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 1, 2018, the compensation...
GBT Announces New Employment Inducement Grants
October 04, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on October 1, 2018, the compensation committee of the...
GBT Announces Participation at the 2018 Cantor Global Healthcare Conference
September 26, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Cantor Global Healthcare...
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
January 09, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted...
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
November 13, 2017 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced today that the independent Data and Safety Monitoring Board (DSMB) for the...
Sickle Cell Disease Treatment Market to Reach US$ 584.0 Mn by 2025 – Persistence Market Research
September 26, 2017 11:18 ET
|
Persistence Market Research
New York, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Global sickle cell disease treatment market is expected to witness robust growth during the forecast period. This growth is expected to be primarily...
Global Blood Therapeutics Announces Participation at Three September Conferences
September 03, 2015 07:35 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of...